Home
|
About us
|
Contact us
About AWMSG
All Wales Medicines Strategy Group (AWMSG)
New Medicines Group (NMG)
All Wales Prescribing Advisory Group (AWPAG)
Meetings
Appraisals
Appraisal information
Patients/carers/patient organisations
Healthcare professionals
Pharmaceutical industry
Search and reports
Search and browse
Reports
Medicines management
About
Forthcoming work programme
National prescribing indicators
Clinical effectiveness prescribing programme
Appraisal monitoring
In-patient medication administration record
Patient information leaflets
Library
ambrisentan (Volibris®)
Reference No. 20
Publication date:
11/06/2009
Appraisal information
ambrisentan (Volibris®) 5 mg film-coated tablet
ambrisentan (Volibris®) 10 mg film-coated tablet
Company:
GlaxoSmithKline
BNF category:
Cardiovascular system
NMG meeting date:
12/11/2008
AWMSG meeting date:
29/04/2009
Submission Type:
Independent Review
Status:
Recommended
Advice No:
2508
Ratification by Welsh Government:
10/06/2009
Current Progress
Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government
AWMSG advice
Ambrisentan (Volibris®) is recommended for use within NHS Wales for the treatment of patients with pulmonary arterial hypertension (PAH) classified as World Health Organisation (WHO) functional class (FC) II and III, to improve exercise capacity. Ambrisentan (Volibris®) is restricted for use as directed by a physician experienced in the treatment of PAH at one of the National Commissioning Group (NCG) centres across the UK. Ambrisentan (Volibris®) is not considered suitable for shared care within NHS Wales.
Final Appraisal Recommendation (FAR)
Download
ambrisentan (Volibris) 20 FAR